![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through the agreement with Silk Road Therapeutics to acquire novel topical muco-adherent formulation of Trental (pentoxifylline), a treatment for oral ulcers in patients suffering from behcet's disease.
Lead Product(s): Pentoxifylline
Therapeutic Area: Rare Diseases and Disorders Product Name: Trental
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Poolbeg Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 30, 2024
Details:
Trental-Generic (pentoxifylline) is an oral small molecule drug. It is now approved for the treatment of chronic occlusive arterial disease of the limbs.
Lead Product(s): Pentoxifylline
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Trental-Generic
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
The option agreement grants Soligenix the right to acquire a novel topical formulation of SRT001 (pentoxifylline), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient's suffering from Behçet's Disease (BD).
Lead Product(s): Pentoxifylline
Therapeutic Area: Rare Diseases and Disorders Product Name: SRT001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Soligenix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 01, 2023